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Intragenic Copy Number Variation within Filaggrin
Contributes to the Risk of Atopic Dermatitis with a
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Heather J. Cordell5, W.H. Irwin McLean1 and Alan D. Irvine3,6
Loss-of-function variants within the filaggrin gene (FLG) increase the risk of atopic dermatitis. FLG also
demonstrates intragenic copy number variation (CNV), with alleles encoding 10, 11, or 12 filaggrin monomers;
hence, CNV may affect the amount of filaggrin expressed in the epidermis. A total of 876 Irish pediatric atopic
dermatitis cases were compared with 928 population controls to test the hypothesis that CNV within FLG affects
the risk of atopic dermatitis independently of FLG-null mutations. Cases and controls were screened for CNV
and common FLG-null mutations. In this population the 11-repeat allele was most prevalent (allele frequency
51.5%); the 10-repeat allele frequency was 33.9% and the 12-repeat allele frequency was 14.6%. Having excluded
FLG mutation carriers, the control group had a significantly higher number of repeats than cases (w2 P¼ 0.043),
and the odds ratio of disease was reduced by a factor of 0.88 (95% confidence interval 0.78–0.98, P¼ 0.025) for
each additional unit of copy number. Breakdown products of filaggrin were quantified in tape-stripped stratum
corneum from 31 atopic dermatitis patients and urocanic acid showed a positive correlation with total copy
number. CNV within FLG makes a significant, dose-dependent contribution to atopic dermatitis risk, and
therefore treatments to increase filaggrin expression may have therapeutic utility.
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INTRODUCTION
Atopic dermatitis (eczema) is an itchy inflammatory skin disease
that affects B10.7% of children in the United States (Shaw
et al., 2011) and up to 25% in the United Kingdom (Kay et al.,
1994; Shamssain, 2007). Atopic dermatitis can cause significant
morbidity (Lewis-Jones, 2006) and the associated family stress is
a substantial social and financial burden (Williams, 2005).
Loss-of-function mutations in the filaggrin gene (FLG;
OMIM *135940) cause the dry scaly skin condition ichthyosis
vulgaris (Smith et al., 2006) (OMIM #146700) and are
strongly and significantly associated with atopic dermatitis
(Palmer et al., 2006; Rodrı´guez et al., 2009; van den Oord
and Sheikh, 2009). FLG is expressed in terminally differ-
entiating keratinocytes in the outermost layers of the human
epidermis as a large, insoluble polyprotein, profilaggrin. Each
inactive profilaggrin molecule is dephosphorylated and
cleaved into 10, 11, or 12 functional filaggrin monomers
(Gan et al., 1990; Sandilands et al., 2007b). Filaggrin plays a
key role in epithelial barrier function: it aggregates and aligns
keratin bundles in the cornified cell envelope and is further
degraded to release hygroscopic amino acids, constituents of
the ‘‘natural moisturizing factor’’ in human skin (Rawlings
and Harding, 2004; Sandilands et al., 2009).
FLG is located within the epidermal differentiation
complex on chromosome 1q21, a dense cluster of genes
involved in keratinocyte differentiation (Mischke et al.,
1996). FLG belongs to the ‘‘fused’’ S100 gene family,
characterized by a repetitive sequence in a large third exon
(Sandilands et al., 2009). The human FLG gene is poly-
morphic, with common allelic variants showing 10, 11, or 12
nearly identical tandem repeats in exon 3, each B972 bp in
length (Gan et al., 1990; Sandilands et al., 2007b). The FLG
locus therefore demonstrates intragenic copy number varia-
tion, using the definition of copy number variation (CNV)
proposed by Redon et al. (2006) and Alkan et al. (2011). Each
repeat at the DNA level encodes a complete copy of the 324
amino-acid filaggrin polypeptide, the functional protein
product of the gene. Alleles encode 10, 11, or 12 copies of
the filaggrin monomer, and consequently CNV may affect the
quantity of filaggrin expressed in the epidermis.
See related commentary on pg 10ORIGINAL ARTICLE
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Early CNV studies, based on BAC (Bacterial Artificial
Chromosome) arrays or low-resolution oligonucleotide plat-
forms, were able to identify CNVs 4100 kb (Iafrate et al.,
2004; Sebat et al., 2004; Redon et al., 2006; Alkan et al.,
2011). More recent studies have achieved genome-wide
assessment of CNVs above 450–500 bp in length using
comparative genomic hybridization (Conrad et al., 2010;
Craddock et al., 2010), but this technique currently lacks the
power to study rare alleles or to detect an odds ratio ofo1.4
(Craddock et al., 2010). We therefore used detailed PCR-
based genotyping strategies to define size variants of exon 3
of FLG to investigate whether CNV contributes to the risk of
atopic dermatitis.
RESULTS
A case–control study using a total of 925 Irish pediatric atopic
dermatitis cases and 998 Irish population controls was used
to test the hypothesis that CNV within FLG affects atopic
dermatitis risk. Of these, 876 cases (94.7%) and 928 controls
(93.0%) were successfully genotyped; the demographic and
clinical data are summarized in Table 1.
FLG copy number variants in the Irish population
A total of 100 consecutive atopic dermatitis cases were
screened by long-range PCR and there was no evidence of
CNV within the 50 portion of FLG exon 3, representing
repeats numbered 1 to 7 (Figures 1 and 2). All 925 cases and
998 controls were screened using a separate long-range PCR
to identify copy number variation within the 30 portion of FLG
exon 3, representing repeats 7 to the end of the repetitive
region (Figures 1 and 3) and a TaqMan allelic discrimination
assay for single-nucleotide polymorphism (SNP) rs12730241.
In the Irish control population, the most prevalent allele size
was 11 repeats, representing 51.5% of alleles; the 10-repeat
allele frequency was 33.9% and the 12-repeat allele
frequency was 14.6%. Allele counts in cases and controls
are summarized in Table 2.
FLG-null mutation screening
All four prevalent FLG-null mutations were successfully typed
in 855 out of the 876 (97.6%) cases genotyped for copy
number and 926 out of 928 (99.8%) controls genotyped for
copy number. Of the fully genotyped individuals, 327 (38.2%)
of cases and 102 (11.0%) of controls carried one or two FLG-
null mutations; 528 cases and 824 controls were of wild-type
genotype for the four FLG-null mutations (Table 1).
FLG copy number affects the risk of atopic dermatitis
FLG-null mutation carriers were excluded from further
analysis to allow independent assessment of the CNV effect.
After exclusion of the FLG-null mutation carriers, w2 testing
showed a significantly higher total copy number in the
controls than in the atopic dermatitis cases (P¼0.043).
Furthermore, logistic regression analysis of the total copy
number as continuous data (considering 20, 21, 22, 23, and
24 copies) showed that the addition of each subsequent
filaggrin-encoding unit reduces the odds ratio of disease by a
factor of 0.88 (95% confidence interval 0.78–0.98,
P¼0.025). Therefore, an individual having two 12-repeat
alleles, compared with an individual with two 10-repeat
alleles, has a risk reduction of 0.88 to the power of 4,
meaning a 0.60 times reduced risk of developing atopic
dermatitis.
The concentrations of filaggrin breakdown products correlate
with FLG copy number
Linear regression analysis comparing filaggrin breakdown
products quantified by HPLC of tape-stripped stratum
corneum from 31 atopic dermatitis cases (Kezic et al.,
2011) showed a small but statistically significant correlation
between urocanic acid concentration (UCA) and FLG total
copy number (r¼0.42, P¼0.018; Supplementary Figure S1a
online). The value r2¼ 0.18 indicates that 18% of the
variation of UCA in the stratum corneum samples may be
attributed to FLG CNV. The concentrations of two other
breakdown products of filaggrin, histidine and pyrrolidone-5-
carboxylic acid (PCA), each also showed a small positive
correlation with FLG total copy number (histidine r¼0.20,
PCA r¼0.28) but these were not statistically significant
(Supplementary Figure S1b and c online).
DISCUSSION
Assessment of the entire range of genetic and genomic
variation (including SNPs, structural variation, noncoding
variants, long-range trans effects, and so on) will be required
in order to fully understand the genetic predisposition to
Table 1. Demographic and clinical data relating to atopic dermatitis cases and unselected population controls
Irish pediatric atopic dermatitis cases Irish population controls
Genotyped collection
(n=876)
Filaggrin (FLG) mutation carriers
excluded (n=528)
Genotyped collection
(n=928)
FLG mutation carriers
excluded (n=824)
Male sex, number (%) 545 (62.2) 332 (62.9) 278 (30.0) 251 (30.5)
Mean age, years (SD) 3.3 (3.5) 3.0 (3.3) 36.2 (12.4) 36.2 (12.5)
Nottingham eczema severity score,
mean (SD)
11.2 (2.6) 11.0 (2.5) Not known Not known
The diagnosis of atopic dermatitis was made by experienced dermatologists according to the United Kingdom diagnostic criteria (Williams et al., 1994) with
disease severity scored according to the Nottingham Eczema Severity Score, in which 1 to 8 denotes mild atopic dermatitis, 9 to 11 is moderate, and 12 to 15
defines severe disease (Emerson et al., 2000). The control population represents consecutive successfully genotyped Trinity Biobank Control samples,
derived from Irish adult blood donors.
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complex traits such as atopic dermatitis. Loss-of-function
mutations in FLG represent the strongest and most significant
genetic factor in the etiology of atopic dermatitis character-
ized to date (Baurecht et al., 2007; Rodrı´guez et al., 2009;
van den Oord and Sheikh, 2009), with an odds ratio
estimated by meta-analysis to be 3.12 (Baurecht et al.,
2007). This study contributes to the understanding of
haploinsufficiency in atopic dermatitis by showing that
CNV within FLG also significantly affects atopic dermatitis
risk. The CNV effect is independent of FLG-null mutations but
the overall effect size is smaller, as the comparable odds ratio
is 1/0.88¼1.14. However, logistic regression analysis shows
a dose-dependent effect, such that the risk reduces incre-
mentally as the total number of filaggrin monomers encoded
on a pair of alleles increases. Therefore, an individual with 20
filaggrin repeats has an odds ratio of 1/0.60¼ 1.67 compared
with an individual having a total of 24 repeats. As all of
the size variant alleles are common within the population
(33.9%, 10 repeats; 51.5%, 11 repeats; and 14.6%, 12
repeats), this form of genetic variation represents a significant
additional contribution to AD risk.
Exon 1
(15 bp)
Exon 2
(159 bp)
KEY: Partial repeat Filaggrin repeat (972 bp each) Unique sequence
PCR 1 PCR 2
SNP rs12730241 in LD
with 12-repeat allele
5′ 3′
Exon 3 (12,753 to 14,697 bp)
with 10, 11, or 12 tandem repeats
Untranslated region
(∼ 2,000 bp)
Figure 1. Filaggrin (FLG) structure and genotyping strategies to identify copy number variants. LD, linkage disequilibrium; SNP, single-nucleotide
polymorphism. Diagram adapted from Smith et al. (2006).
8,000 bp
11/12 10/11 10/11
Allele copy numbers
10/11 10/11 10/1111/1211/11
6,000 bp
5,000 bp
4,000 bp
Figure 3. Visualization of PCR 2 products showing product sizes
representing 10-, 11-, and 12-repeat alleles from the 30 portion of filaggrin
(FLG) exon 3. PCR reactions separated on 0.8% agarose gel. Bioline
hyperladder I marker (Bioline).
8,000 bp
6,000 bp
Figure 2. Visualization of PCR 1 products showing no evidence of copy
number variation (CNV) within the 50 portion of filaggrin (FLG) exon 3. PCR
reactions separated on 0.8% agarose gel. Bioline hyperladder I marker
(Bioline, London, UK).
Table 2. FLG genotypes, null mutations, and copy
number variants in 876 Irish atopic dermatitis cases
and 928 Irish population controls
Whole collection
FLG mutation carriers
excluded
Allelic
variant
Atopic
dermatitis
cases, n (%)
Population
controls,
n (%)
Atopic
dermatitis
cases, n (%)
Population
controls,
n (%)
10 Repeats 696 (39.7) 629 (33.9) 410 (38.8) 550 (33.4)
11 Repeats 814 (46.5) 956 (51.5) 497 (47.1) 856 (51.9)
12 Repeats 242 (13.8) 271 (14.6) 149 (14.1) 242 (14.7)
Total copy
number
20 NA NA 85 (16.1) 87 (10.6)
21 NA NA 186 (35.2) 300 (36.4)
22 NA NA 172 (32.6) 294 (35.7)
23 NA NA 75 (14.2) 120 (14.6)
24 NA NA 10 (1.9) 23 (2.8)
w2 test P=0.043
Logistic
regression
P=0.025
Abbreviations: FLG, filaggrin; NA, not applicable.
Total copy number denotes the sum of the number of repeats on each
allele in an individual showing FLG wild-type genotype at the four
prevalent null mutations. The FLG and copy number allelic variants each
did not show a significant deviation from Hardy–Weinberg equilibrium
(P40.05) in the control population.
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The polymorphic FLG alleles segregate in families
according to Mendelian inheritance (Gan et al., 1990) and
therefore may contribute to the observed familial clustering of
atopic disease (Brown and Reynolds, 2006). Filaggrin is a
histidine-rich protein (Lynley and Dale, 1983) and FLG-null
mutations have been shown to affect the quantitative
expression of histidine and subsequent filaggrin breakdown
products in the stratum corneum of atopic dermatitis patients
and control individuals (Kezic et al., 2008, 2011). This study
has shown that CNV within FLG may have a significant
functional effect on the amount of UCA in the stratum
corneum, with a small but significant correlation accounting
for B18% of the variation in UCA concentration. UCA is a
component of the ‘‘natural moisturizing factor’’ in the
epidermis (Rawlings and Harding, 2004) and plays a role in
the maintenance of stratum corneum hydration as well as
being a putative UV photoprotector (Eckhart et al., 2008). The
quantitative data linking FLG CNV with stratum corneum
UCA concentration therefore provide support for the ob-
served genetic epidemiological association. The other filag-
grin breakdown products, histidine and PCA, also showed a
small positive correlation with filaggrin copy number;
however, a larger study is required in order to confirm or
refute these correlations.
Two dermatological disorders have so far been shown to
exhibit CNV as a mechanism contributing to their patho-
genesis: microdeletions on chromosome 17q24.2–q24.3 in
congenital generalized hypertrichosis terminalis with or
without gingival hyperplasia (Sun et al., 2009); and deletions
of the late cornified cell envelope genes LCE3B and LCE3C in
psoriasis (de Cid et al., 2009; Huffmeier et al., 2010). The
extent to which CNV contributes to the ‘‘missing heritability’’
of common complex traits, including psoriasis and atopic
dermatitis, remains to be defined. The three common FLG
allele sizes (10, 11, and 12) have previously been reported in
American and Irish populations (Gan et al., 1990; Ginger
et al., 2005; Sandilands et al., 2007b). Gan et al. (1990)
screened over 300 individuals by Southern blot and showed
that there were approximately equal proportions of 10-, 11-,
and 12-repeat alleles. In our much larger study of the Irish
population, roughly one-third of alleles have 10 repeats, half
have 11 repeats, and the remaining 15% are 12-repeat
alleles. An investigation of 113 individuals from Winnipeg
Canada suggested that the 12-repeat allele may be a
protective factor against self-perceived frequent dry skin
(Ginger et al., 2005), but this study was performed before
knowledge of FLG-null mutations as a cause of common
ichthyosis (Palmer et al., 2006; Brown et al., 2008), and
hence the data are difficult to interpret. In retrospect, it
appears likely that the observed association is attributable
to a risk effect of the two common, ancestral FLG-null
mutations (R501X and 2282del4) that usually do not occur on
the 12-repeat allele (A Sandilands, unpublished data).
It is theoretically possible that the observed association of
copy number with atopic dermatitis risk may be caused by
linkage of the 10-repeat allele to an unrecognized FLG loss-
of-function mutation. However, this is unlikely to account for
the statistically significant association for three reasons: the
prevalence and distribution of FLG-null mutations in the Irish
population is well established (Sandilands et al., 2007b)
and mutations other than the four that were assayed in this
study are rare; furthermore, the statistical analysis of the
continuous data shows an incremental reduction in the risk of
atopic dermatitis with each additional unit of copy number;
finally, the correlation of total copy number with stratum
corneum UCA concentration provides additional evidence of
a stepwise functional effect.
Carriers of the four FLG-null mutations that are prevalent
in the population were excluded from statistical analysis in
order to study the independent effect of CNV on atopic
dermatitis risk. This approach is necessary because FLG-null
mutations have such a profound effect on filaggrin expression,
which is reduced to near zero in homozygotes or compound
heterozygotes (Sandilands et al., 2007b), that the more subtle
effect of CNV could be obscured. It would be interesting to
study the effect of CNV in trans with FLG-null mutations to
investigate the possibility that larger copy number variants
may provide some protection by partially ameliorating the
effect of a FLG-null allele, or conversely the smaller copy
number variants may serve to worsen the phenotype of a
FLG-null heterozygote. However, even the total sample size
of nearly 2,000 individuals in this study was not large enough
to have sufficient power to permit such haplotype analysis. It
would also be interesting to investigate the effect of FLG CNV
on atopic dermatitis severity, with the hypothesis that a greater
number of repeats protects against severe disease whereas a
smaller number of repeats increases the risk of severe disease.
However, this study, having predominantly moderate–severe
atopic dermatitis cases, did not have sufficient statistical
power to draw any firm conclusions regarding the effect of
copy number on disease severity.
Previously published whole-genome association studies of
CNVs focused on eight common complex traits of impor-
tance to human health (Craddock et al., 2010); a separate
study characterized CNVs of 4443 bp in 450 individuals as
reference genotypes from European, East Asian, and African
individuals (Conrad et al., 2010). The careful and rather
laborious genotyping strategy utilized for this study has given
detailed information on size variation within exon 3 of FLG in
nearly 2,000 Irish individuals and the same three size
variants—encoding 10, 11, and 12 copies of the filaggrin
monomer—have been identified. Rarer size variants includ-
ing duplications, a 3.7-kb deletion (Matsuzaki et al., 2009),
and two large inversions involving the FLG locus (Kidd et al.,
2008; Pang et al., 2010) are recorded as single cases in the
UCSC (University of California, Santa Cruz) database. Large
inversions and other structural variants may not have been
detected using our PCR-based genotyping assays and these
cases may have contributed to the 5.3% of cases and 7.0% of
controls in whom CNV genotyping failed. In contrast to
human FLG, mouse strains show a wide range of CNV within
the orthologous murine gene (flg), where characterized
strains show between 10 and 20 filaggrin subunits (Zhang
et al., 2002). Although this study focused on CNV of 972 bp
sequences within FLG exon 3, it is clearly possible that larger
duplications of the whole FLG third exon or indeed the entire
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FLG gene may occur. In light of the dose-dependent effect of
intragenic CNV, these larger CNVs would be expected to
have an even greater effect on filaggrin ‘‘dose’’ in the
epidermis and warrant further investigation.
The discovery that FLG-null mutations are a strong and
significant risk factor for atopic dermatitis has already led to
a greater understanding of the importance of skin barrier
function in atopic disease (Sandilands et al., 2009). The fact
that CNV within FLG significantly affects atopic dermatitis
risk raises the attractive possibility that treatments aimed at
increasing filaggrin expression may have a therapeutic effect
on the prevention and/or treatment of atopic dermatitis.
Encouragingly, our data show that even a 5–10% increase
in filaggrin ‘‘dose’’ results in a significant reduction in the
incidence of atopic dermatitis. Furthermore, as this analysis
excluded FLG-null mutation carriers, the benefit is not likely to
be restricted to the B10% of individuals in the population
who carry a FLG-null mutation (Smith et al., 2006; Sandilands
et al., 2007a). It is perhaps surprising to observe that a 5–10%
increase in filaggrin copy number is sufficient to result in
a reduced risk of atopic dermatitis. There is likely to be
considerable inter- and intra-individual variation in the rates
of biosynthesis, processing, and degradation of filaggrin, but
it may be speculated that the life-long effect of a genetically
determined 5–10% increase in filaggrin ‘‘dose’’ may provide
sufficient enhancement to skin barrier function to result in
the observed risk reduction. Feasibility studies are currently
underway in the United Kingdom and United States (Feasi-
bility Study of Barrier Enhancement for Eczema Prevention
(BEEP); The BEEP Study—Feasibility study of Barrier Enhance-
ment for Eczema Prevention) in preparation for a prospective
clinical trial to investigate whether intensive emollient
application in early life, with the aim of improving skin barrier
function, may reduce the risk of atopic dermatitis in infancy.
In the future, it may also be possible to target pathways that
control filaggrin expression with small molecules and thereby
develop therapeutics to boost filaggrin expression in the
epidermis. It is hoped that these combined investigations will
demonstrate the translation of functional genomics to better
care for atopic dermatitis patients in the foreseeable future.
MATERIALS AND METHODS
Atopic dermatitis cases
A collection of 925 unrelated Irish pediatric atopic dermatitis cases
was recruited through a tertiary referral dermatology clinic at one
center, Our Lady’s Children’s Hospital, Crumlin, Dublin. Atopic
dermatitis was defined according to the UK diagnostic criteria
(Williams et al., 1994) and all cases were confirmed on examination
by an experienced dermatologist. In all, 51.2% of cases had severe
disease; 32.6% had moderate, and 16.2% had mild atopic
dermatitis, defined according to the Nottingham Eczema Severity
Score (Emerson et al., 2000). Demographic and clinical data are
summarized in Table 1. Carriers of the four FLG-null mutations that
are prevalent in the Irish population (R501X, 2282del4, S3247X, and
R2447X) were excluded from subsequent statistical analysis in order
to study the independent effect of CNV on atopic dermatitis risk. The
genetic architecture of FLG loss-of-function mutations has been
extensively characterized in the Irish population (Sandilands et al.,
2007b; Chen et al., 2011), and together these four mutations account
for 495% of FLG mutations; the remaining o5% are composed of
rare and family-specific mutations.
Control population
A total of 998 control DNA samples were obtained from the Trinity
College Dublin Biobank, representing an unselected Irish popula-
tion, as described previously (O’Donovan et al., 2008). Demo-
graphic data relating to the control population are summarized in
Table 1. As with the case collection, carriers of the four prevalent
FLG-null mutations in the control population were excluded from
subsequent statistical analysis.
Ethical considerations
This study was conducted with the approval of the local research
ethics committee (Our Lady’s Children’s Hospital, Crumlin). A
parent or guardian for each case and all control subjects gave written
informed consent. The collection of DNA samples and clinical data
were conducted in accordance with the Good Clinical Practice and
the Declaration of Helsinki Principles.
Genotyping strategy
The four FLG loss-of-function mutations that are most prevalent in the
Irish population (R501X, 2282del4, S3247X, and R2447X) were
screened in the cases and controls as previously described (Sandilands
et al., 2007b; O’Regan et al., 2010). Copy number variants were
distinguished by their different sized products following PCR
amplification. Amplification of the whole of exon 3 results in rather
large products, ranging from 12,413 to 14,357 base pairs, within
which size variants are difficult to distinguish reliably with the
necessary resolution of 1,000 base pairs. Long-range PCR reactions
were therefore designed to amplify the region of interest in two
partially overlapping portions (Figure 1) as follows. In the first PCR
reaction (PCR 1), the 50 portion of FLG exon 3, from intron 2 (at a point
near exon 3) to repeat 7, was amplified by long-range PCR using
primers listed in Table 3. PCR reactions (50ml) were performed using
Table 3. PCR primers for amplification of FLG exon 3
PCR reaction Forward primer sequence Reverse primer sequence Product sizes (bp)
Amplification of beginning
of exon 3 to repeat 7 (PCR 1)
50-GCTGATAATGTGATTCTGTCTG-30 50-CTGGCTAAAACTGGATCCCCA-30 7,624
Amplification of repeat
7 to 30 partial repeat (PCR 2)
50-CCCAGGACAAGCAGGAACT-30 50-CTGCACTACCATAGCTGCC-30 4,277, 5,249, and 6,224
Abbreviations: bp, base pairs; FLG, filaggrin.
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the TaKaRa LA Taq (Takara Bio, Shiga, Japan) with 200 ng genomic
DNA, 1 unit of TaKaRa LA Taq, 8ml dNTPs (2.5 mM each), 25 ng each
of the forward and reverse primers, 5ml 10 Buffer (TaKaRa), and
5ml MgCl (25 mM). Cycle conditions for PCR 1 were as follows: 94 1C
initial denaturation for 1 minute, followed by 33 cycles of denatura-
tion (94 1C for 30 seconds) and elongation (68 1C for 10 minutes),
followed by a final elongation at 72 1C for 10 minutes. Electrophoresis
on a 0.8% w/v agarose gel, at 120 V for 3 hours, was used to identify
product size. In a second PCR reaction (PCR 2), the 30 portion of FLG
exon 3, encompassing repeats 7 to 10 plus the 30 partial repeat, was
amplified by long-range PCR using the primers shown in Table 3.
Reactions (20ml) were performed using the Expand High Fidelity
System (Roche Applied Science, Mannheim, Germany) with
B100 ng genomic DNA, 1.5 units of Expand High Fidelity enzyme,
2ml dNTPs (2.5 mM each), 10 ng each of the forward and reverse
primers, 2ml Buffer 2 (Roche Expand High Fidelity System), and 4% v/
v DMSO. Cycle conditions for PCR 2 were as follows: 95 1C initial
denaturation for 5 minutes, followed by 35 cycles of denaturation
(94 1C for 30 seconds), annealing (63.5 1C for 30 seconds) and
elongation (72 1C for 5 minutes 30 seconds), followed by a final
elongation at 72 1C for 7 minutes. Products were separated as for PCR
1, on a 0.8% w/v agarose gel.
The largest product from PCR 2 is most at risk of suboptimal
amplification, resulting in a weaker band when visualized on a gel
under UV light. In order to minimize the risk of failing to detect the
largest size allele, an additional SNP genotyping strategy was used.
SNP rs12730241 is in the 30 untranslated region of FLG (near to the
duplicated repeats) and was shown, in 89 out of 90 (98.9%) fully
sequenced individuals, to be associated with the 12-repeat allele.
Rs12730241 was typed using the available predesigned TaqMan
allelic discrimination assays (Applied Biosystems, Foster City, CA)
according to the manufacturer’s recommended protocols. Therefore,
12-repeat alleles shown by long-range PCR were confirmed by
genotyping for SNP rs12730241.
Quantification of filaggrin breakdown products
Data relating to the most abundant filaggrin breakdown products—
histidine, UCA, and PCA—in 31 FLG wild-type atopic dermatitis
cases were available from a previous study (Kezic et al., 2011).
Stratum corneum samples removed from the nonlesional skin of
pediatric atopic dermatitis cases by a tape-stripping technique had
undergone HPLC to quantify histidine, UCA, and PCA as previously
described (Kezic et al., 2011).
Statistical analysis
In individuals with a wild-type genotype at the four screened
FLG-null mutations, total copy number was defined as the sum
of the number of tandem repeats on each allele. Total copy number
genotype frequencies were compared between the case and control
groups using w2 test and logistic regression analysis, performed with
the statistical analysis package Stata (StataCorp LP, College Station,
TX). Simple linear regression was used to test for correlation between
total copy number and FLG breakdown products using SPSS v 15.0.1
(IBM Corporation, Somers, NY).
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